IN2COVID: Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

Sponsor

Pontificia Universidad Catolica de Chile (Other)

Overall Status

Completed

CT.gov ID

NCT04988217

Collaborator

Altum Pharmaceuticals INC (Industry)

173

Enrollment

Location

Arms

10.4

Actual Duration (Months)

16.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The IN2COVID Study is a 2-staged phase I/II double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of AP-003 (Interferon α2b) when administered via inhalation twice daily for 10 days. Participants will have a final visit at Day 11.

A lead-in phase 1 substudy will be performed with at least 18 healthy adult male subjects to assess safety and tolerability of inhaled AP-003 compared to placebo for 10 days. Two cohorts of 9 subjects will be randomly assigned to receive two doses of inhaled AP-003 or placebo with an allocation ratio of 2:1. The first cohort will assess a dose of 2.5 MIU of inhaled AP-003. If no adverse events are observed, the second cohort will be conducted using a dose of 5 MIU of inhaled AP-003. Maximum tolerated dose will be determined in this phase 1 substudy.

After the completion of phase 1, the study will continue with a phase 2 treatment RCT in patients with COVID-19. In this phase, 150 adults with mild or moderate COVID-19 demonstrated by SARS-CoV-2 positive polymerase chain reaction (PCR) ≤ 5 days at enrollment will be randomized 1:1 (75 in each arm) to receive nebulized AP-003 or identical placebo twice daily during 10 days.

Condition or Disease	Intervention/Treatment	Phase
Coronavirus Disease 2019	Drug: Interferon-Alpha2B Drug: Placebo	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

173 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Phase I/II Randomized, Double-blind, Placebo-controlled Study of Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

Actual Study Start Date :

Sep 15, 2021

Actual Primary Completion Date :

Apr 15, 2022

Actual Study Completion Date :

Jul 28, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Part 1a: Interferon alpha 2b 2.5 MIU Nebulized interferon alpha 2b 2.5 MIU every 12 hours during 10 days (20 doses total)	Drug: Interferon-Alpha2B Nebulized interferon alpha 2B Other Names: AP-003
Experimental: Part 1b: Interferon alpha 2b 5 MIU Nebulized interferon alpha 2b 5 MIU every 12 hours during 10 days (20 doses total)	Drug: Interferon-Alpha2B Nebulized interferon alpha 2B Other Names: AP-003
Placebo Comparator: Part 1: Placebo Nebulized placebo every 12 hours during 10 days (20 doses total)	Drug: Placebo Nebulized placebo
Experimental: Part 2: Interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1) Nebulized interferon alpha 2b 5 MIU (or maximum tolerated dose from part 1) every 12 hours during 10 days (20 doses total)	Drug: Interferon-Alpha2B Nebulized interferon alpha 2B Other Names: AP-003
Placebo Comparator: Part 2: Placebo Nebulized placebo every 12 hours during 10 days (20 doses total)	Drug: Placebo Nebulized placebo

Outcome Measures

Primary Outcome Measures

Treatment-emergent adverse events in healthy subjects [At the end of Phase 1 (Phase 1 is 11 days)]
Safety and tolerability of AP-003 as measured by subject incidence of treatment-emergent adverse events.
Change in perception of health status measured by EQ VAS in COVID-19 patients [At Day 5 of Phase 2 (Phase 2 is 28 days)]
Changes from baseline evaluation in COVID-19(+) participants' perception of health status at Day 5 as measured by EQ VAS in AP-003 treated patients compared to placebo.

Secondary Outcome Measures

Serum levels of interferon alpha 2b [Up to Day 11 of Phase 1 (Phase 1 is 11 days)]
Pharmacokinetics of nebulized AP-003 in healthy adults assessed by serial serum quantification of interferon alpha 2b
Expression of interferon-induced genes in blood sputum samples [Up to Day 11 of Phase 1 (Phase 1 is 11 days)]
Evaluation of interferon-induced biomarkers after treatment with AP-003 in blood and sputum of healthy adults to assess biological effect of Interferon
Change in perception of health status measured by EQ VAS [Day 10 of Phase 2 (Phase 2 is 28 days)]
Changes in participants' perception of health status from baseline to Day 10 as measured by EQ VAS in AP-003 treated patients compared to placebo.
Change in perception of health status measured by EQ VAS [Day 28 of Phase 2 (Phase 2 is 28 days)]
Changes in participants' perception of health status from baseline to Day 28 as measured by EQ VAS in AP-003 treated patients compared to placebo.
Change in EuroQoL Quality of Life instrument (EQ-5D-5L) [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
Changes in participants' perception of health status from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by EuroQoL Quality of Life instrument (EQ-5D-5L).
Change in Ordinal Scale for Clinical Improvement [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
Changes in participants' overall health from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by Ordinal Scale for Clinical Improvement in AP-003 treated patients compared to placebo.
Improvement in clinical symptoms [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
Changes in participant's improvement in clinical symptoms from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by a daily symptom diary in AP-003 treated patients compared to placebo.
Emergency department visits [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
The proportion of participants attending an emergency department for COVID-19 by Day 28 in AP-003 treated patients compared to placebo.
Hospitalizations [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
The proportion of participants hospitalized for COVID-19 by Day 28 in AP-003 treated patients compared to placebo.
Duration of hospitalization [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
For hospitalized participants, duration of hospitalization in AP-003 treated patients compared to placebo.
Time from consent to clinical deterioration [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
Time from consent to clinical deterioration defined as requiring or recommended for ventilatory support (continuous positive airway pressure [CPAP] or ventilator), shock requiring vasopressor support, and/or heart failure (defined as left ventricular ejection fraction [LVEF] < 30%) in AP-003 treated patients compared to placebo.
Change in SARS CoV-2 viral load [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
SARS CoV-2 viral load by quantitative PCR from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 in AP-003 treated patients compared to placebo.
Change in inflammatory parameters [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
Changes in D dimer, CRP, Ferritin, Troponin, creatine phosphokinase (CPK), LDH, IL-6 from baseline through Day 28 in AP-003 treated patients compared to placebo.
Organ failure rate [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
Organ failure, any organ, from consent through Day 28 in AP-003 treated patients compared to placebo.
Death rate [Up to day 28 of Phase 2 (Phase 2 is 28 days)]
Death, any cause, from consent through Day 28 in AP-003 treated patients compared to placebo.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Phase 1 stage:

Inclusion criteria:

Male subjects aged 18-50 years;
In good state of health, determined by medical history, physical exam, and normal laboratory tests at screening;
Are able to provide informed consent for participation;
Are able and willing to comply with the study schedule and procedures.

Exclusion Criteria

Active SARS-CoV-2 infection demonstrated by positive polymerase chain reaction (PCR) at enrollment;
Requiring CPAP for sleep apnea;
Pre-existing pulmonary disease;
Have any serious acute concomitant illness that, in the opinion of the investigator, would interfere with evaluation of safety of AP-003, or put the participant at risk of harm from study participation;
Are currently receiving an investigational agent, have participated in another study of an investigational agent within 30 days of enrollment, or were previously enrolled in the current study;
Are legally incompetent and unable to understand the study's purpose, significance, and consequences, and to make decisions accordingly;
Have known hypersensitivity to interferon alpha or any component of the study drug or placebo control.

Phase 2 stage:

Inclusion criteria:

Active SARS-CoV-2 infection demonstrated by positive polymerase chain reaction (PCR) ≤ 5 days at enrollment;
Symptomatic of mild or moderate COVID-19 for ≤ 5 days at enrollment. Symptoms can include fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, chest pain, with or without shortness of breath on exertion/dyspnea;
Age ≥ 18 years;
Are able to provide informed consent for participation;
Are able and willing to comply with the study schedule and procedures.

Exclusion Criteria

Patients requiring CPAP for sleep apnea.
Patients with pre-existing pulmonary disease requiring chronic O2 supplementation.
Patients with known infection with Influenza A or B;
In the opinion of the Investigator, should undergo ventilatory (CPAP, mechanical ventilation, etc.) or circulatory support within 24 hours of study enrollment;
Have any serious acute concomitant illness that, in the opinion of the Investigator, would interfere with evaluation of safety or efficacy, or put the participant at risk of harm from study participation;
Are currently receiving an investigational agent, have participated in another study of an investigational agent within 30 days of enrollment, or were previously enrolled in the current study;
Are legally incompetent and unable to understand the study's purpose, significance, and consequences, and to make decisions accordingly;
Women who are pregnant or breast-feeding, or planning to conceive in the next 30 days;
Have known hypersensitivity to interferon alpha or any component of the study drug or placebo control.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Red de Salud UC Christus	Santiago	RM	Chile	8330033

Sponsors and Collaborators

Pontificia Universidad Catolica de Chile
Altum Pharmaceuticals INC

Investigators

Study Director: Arturo Borzutzky, M.D., Pontificia Universidad Catolica de Chile
Principal Investigator: Diego García-Huidobro, M.D., Ph.D., Pontificia Universidad Catolica de Chile
Principal Investigator: Carolina Iturriaga, R.N., Pontificia Universidad Catolica de Chile
Principal Investigator: Jose A Castro-Rodríguez, M.D., Ph.D., Pontificia Universidad Catolica de Chile
Principal Investigator: Eleanor Fish, Ph.D., University Health Network, Toronto, Canada